版本:
中国

BRIEF-Celsion says data monitoring committee recommends optima study continuation

Nov 30 Celsion Corp :

* Press release - Celsion announces data monitoring committee unanimously recommends continuation of phase III optima study of Thermodox for primary liver cancer

* Celsion Corp says expects to complete patient enrollment in this 550 patient trial by early 2018 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐